Beyond Air, Inc., formerly AIT Therapeutics, Inc., is a medical device company. The Company is focused on developing a nitric oxide (NO) generator and delivery system that generates NO from ambient air. The Beyond Air NOGDS is designed to deliver a dosage of NO to the lungs. The Company focuses on areas, such as persistent pulmonary hypertension of the newborn (PPHN), bronchiolitis (BRO) and nontuberculous mycobacteria (NTM). Its Beyond Air NOGDS also delivers a high concentration of NO to the lungs. The Company’s products include Beyond Air- PH, Beyond Air- BRO and Beyond Air- NTM.
Market Cap:88.9M; Shares Outstanding:13.4M; Short Interest: 30.2%; Q2 2020(6/30/19): Cash 9.38M. Loss 4.1M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 16，no change
Shares hold: 1625.2k shares. no change
shares% hold: 11.63%，no change